ARTICLE | Targets & Mechanisms
EMMPRIN's new clothes
February 17, 2011 8:00 AM UTC
EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc.'s antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might be worthwhile to revisit this extracellular matrix metalloproteinase inducer in multiple sclerosis.1 The researchers
have antibodies against the target and are seeking an industry...